Patents Assigned to Weizmann Institute of Science
-
Patent number: 8200648Abstract: A method includes finding regions of a reference signal which provide at least one of: local evidence scores and a global evidence score. The local evidence scores indicate local similarity of the regions of the reference signal to regions of a query signal and the global evidence score defines the extent of a global similarity of the query signal to the reference signal. A media exploring device is also included which includes an importance encoder and a media explorer. The importance encoder generates importance scores of at least portions of digital media as a function of at least one of local evidence scores and global evidence scores. The media explorer enables exploring through the digital media according to (i) the importance scores, (ii) data associations/links induced by the evidence scores between different portions of the digital media. The device may also include a media player to play the digital media with adaptive speeds as a function of the importance scores.Type: GrantFiled: August 7, 2007Date of Patent: June 12, 2012Assignee: Yeda Research & Development Co. Ltd. at the Weizmann Institute of ScienceInventors: Oren Boiman, Michal Irani
-
Patent number: 8106010Abstract: The present invention relates to anti-angiogenic variants of pigment epithelium derived factor (PEDF) comprising a plurality of altered phosphorylation sites, polynucleotides encoding same and uses thereof. In particular, the PEDF variants of the present invention provide superior anti-angiogenic activity and high neurotrophic activity and are useful in treating diseases associated with neovascularization and with neurodegenerative conditions.Type: GrantFiled: November 14, 2006Date of Patent: January 31, 2012Assignee: Yeda Research and Development Co. Ltd. at the Weizmann Institute of ScienceInventors: Galia Maik-Rachline, Rony Seger
-
Publication number: 20110300559Abstract: The present invention relates to antibodies specific for human Beclin-1 protein phosphorylated at position Thr 119 and uses thereof. In particular, these antibodies are useful in diagnosing diseases associated with impaired autophagy including cancer and neurodegenerative diseases. The invention further relates to human Beclin-1 mutated at position 119 with a phospho-mimicking residue and uses thereof for treating cancer and neurodegenerative diseases.Type: ApplicationFiled: June 3, 2011Publication date: December 8, 2011Applicant: Yeda Research and Development Co. Ltd. at the Weizmann Institute of ScienceInventors: Adi Kimchi, Einat Zalckvar
-
Publication number: 20110301093Abstract: The present invention relates to antibodies specific for human Beclin-1 protein phosphorylated at position Thr 119 and uses thereof. In particular, these antibodies are useful in diagnosing diseases associated with impaired autophagy including cancer and neurodegenerative diseases. The invention further relates to human Beclin-1 mutated at position 119 with a phospho-mimicking residue and uses thereof for treating cancer and neurodegenerative diseases.Type: ApplicationFiled: June 3, 2011Publication date: December 8, 2011Applicant: Yeda Research and Development Co. Ltd. at the Weizmann Institute of ScienceInventors: Adi Kimchi, Einat Zalckvar
-
Publication number: 20110288159Abstract: A nucleic acid construct and construct system are disclosed. The nucleic acid construct and system comprise a regulatory sequence which regulates inducible expression of a polypeptide of interest, the regulatory sequence comprising a choroid plexus specific promoter, with the proviso that the choroid plexus specific promoter is not a transthyretin promoter. Pharmaceutical compositions comprising same and uses thereof are also disclosed.Type: ApplicationFiled: March 25, 2009Publication date: November 24, 2011Applicant: Yeda Research and Development Co. Ltd. at the Weizmann Institute of ScienceInventor: Alon Chen
-
Publication number: 20110256165Abstract: The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses.Type: ApplicationFiled: June 20, 2011Publication date: October 20, 2011Applicants: B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., Yeda Research and Development Co., Ltd. at the Weizmann Institute of ScienceInventors: Irun R. Cohen, Bracha Rager-Zisman, Angel Porgador, Johannes Herkel
-
Publication number: 20110245657Abstract: A malignancy classification method and medium for diagnosing a region of lung tissue based on MRI data are disclosed. The classifying includes: setting time points T1 and T2 measured from injection of a contrast agent. T1 represents a wash-in time point for malignant lung tissue at which a first concentration value of the injected contrast agent is substantially equal to or near a peak for injected contrast agent concentration in the region of lung tissue. Patient concentration values of the contrast agent for the area of lung tissue at time points T1 and T2 are obtained, and a malignancy classification for the region of lung tissue is provided by comparing the obtained sample concentration values with a predetermined malignancy profile. A visual representation of the malignancy classification of the region of lung tissue is outputted.Type: ApplicationFiled: April 21, 2011Publication date: October 6, 2011Applicant: Yeda Research & Development Co. Ltd. at the Weizmann Institute of ScienceInventors: Hadassa Degani, Edna Haran
-
Publication number: 20110229905Abstract: The present invention relates to antibodies specific for human Beclin-1 protein phosphorylated at position Thr 119 and uses thereof. In particular, these antibodies are useful in diagnosing diseases associated with impaired autophagy including cancer and neurodegenerative diseases. The invention further relates to human Beclin-1 mutated at position 119 with a phospho-mimicking residue and uses thereof for treating cancer and neurodegenerative diseases.Type: ApplicationFiled: December 6, 2009Publication date: September 22, 2011Applicant: Yeda Research and Development Co. Ltd. at the Weizmann Institute of ScienceInventors: Adi Kimchi, Einat Zalckvar
-
Publication number: 20110171206Abstract: A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings.Type: ApplicationFiled: August 19, 2009Publication date: July 14, 2011Applicant: Yeda Research And Development Co., Ltd. at the Weizmann Institute of ScienceInventors: Michael Sela, Yosef Yarden, Bilha Schechter, Tsipi Ben-Kasus
-
Publication number: 20110151538Abstract: The present invention is directed to truncated dockerin polypeptides, recombinant polypeptides and affinity systems comprising the truncated dockerin polypeptide, methods of generating same, and methods of use thereof to purify, isolate, and detect molecules of interest.Type: ApplicationFiled: August 9, 2009Publication date: June 23, 2011Applicants: RAMOT AT TEL-AVIV UNIVERSITY LTD., YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCEInventors: Edward A. Bayer, Alon Karpol, Raphael Lamed
-
Publication number: 20110152525Abstract: The present invention provides novel ruthenium based catalysts, and a process for preparing amines, by reacting a primary alcohol and ammonia in the presence of such catalysts, to generate the amine and water. According to the process of the invention, primary alcohols react directly with ammonia to produce primary amines and water in high yields and high turnover numbers. This reaction is catalyzed by novel ruthenium complexes, which are preferably composed of quinolinyl or acridinyl based pincer ligands.Type: ApplicationFiled: August 10, 2009Publication date: June 23, 2011Applicant: Yeda Research and Development Co. Ltd. at the Weizmann Institute of ScienceInventors: David Milstein, Chidambaram Gunanathan
-
Publication number: 20110093986Abstract: The present invention discloses that down regulation of the SlMYB12 transcription factor results in the colorless peel y phenotype in tomato fruit. The present invention provides polynucleotides encoding the tomato SlMYB12 transcription factor and genetic markers derived therefrom, useful in the breeding of tomato plants having the colorless peel phenotype and in the production of transgenic plants having altered flavonoid content.Type: ApplicationFiled: June 28, 2009Publication date: April 21, 2011Applicant: Yeda Research and Development Co., Ltd At The Weizmann Institute of ScienceInventors: Asaph Aharoni, Avital Adato, Tali Mandel
-
Patent number: 7919078Abstract: The present invention provides IFN?2 mutants and active fragments, analogs, derivatives, and variants thereof, nucleotide molecules encoding same, pharmaceutical compositions containing the same, and methods utilizing the same for treating cancer, infectious diseases, and autoimmune diseases.Type: GrantFiled: January 4, 2008Date of Patent: April 5, 2011Assignee: Yeda Research and Development Co. Ltd. at the Weizmann Institute of ScienceInventors: Gideon E Schreiber, Laila C. Roisman, Diego Jaitin, Eyal Kalie
-
Patent number: 7914797Abstract: The present invention relates to influenza vaccines for human and veterinary use. In particular, the present invention provides a vaccine able to effect long term and cross-strain protection by including at least two influenza virus epitopes expressed as a chimeric polypeptide wherein at least one epitope is influenza A virus matrix protein epitope and the second epitope is a haemagglutinin peptide epitope.Type: GrantFiled: December 6, 2006Date of Patent: March 29, 2011Assignee: Yeda Research and Development Co. Ltd. at the Weizmann Institute of ScienceInventors: Ruth Arnon, Tamar Ben-Yedidia
-
Patent number: 7897840Abstract: The present invention provides transgenic plants transformed with exogenous nucleic acid encoding a Dunaliella salt-inducible or salt-responsive protein selected from the group consisting of eukaryotic initiation factor 3 (eIF3) subunit, NADPH dependent quinone reductase (QOR), aldo-keto reductase (AKR), bifunctional aspartate kinase-homoserine reductase (AK-HSD) and mitochondrial import membrane translocase subunit (TIM9), or a fragment, homolog or variant thereof. The transgenic plants have increased tolerance to salt as compared to corresponding non-transgenic plants.Type: GrantFiled: September 1, 2005Date of Patent: March 1, 2011Assignees: Hazera Genetics Ltd., Rahan Meristem (1998) Ltd., Yeda Research and Development Co., Ltd. at The Weizmann Institute of ScienceInventors: Ada Zamir, Irena Gokhman, Eli Khayat, Nataly Vinikur, Orna Livneh, Avi Gabai
-
Publication number: 20110026103Abstract: An efficient broadband crystal for wavelength conversion, the crystal being a quasi-phase matched non-linear crystal, having an aperiodic poled structure, each period being tuned, and wherein said tuning varies adiabatically along a length of said crystal from a first end wherein said tuning is a strong negative mismatch to a second end wherein said tuning is a strong positive mismatch or vice versa. The crystal is able to provide efficient wavelength conversion over a range of frequencies.Type: ApplicationFiled: March 25, 2009Publication date: February 3, 2011Applicant: Yeda Research And Development Co., Ltd. at the Weizmann Institute of ScienceInventors: Haim Suchowski, Yaron Silberberg
-
Publication number: 20110027341Abstract: The present invention relates to a drug delivery device that is useful for topical treatment of various infections such as skin and nail, or vaginal infections.Type: ApplicationFiled: March 26, 2009Publication date: February 3, 2011Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD. at the Weizmann Institute of ScienceInventors: David Mirelman, Aharon Rabinkov
-
Publication number: 20110006674Abstract: A method for fabrication of substrate having a nano-scale surface roughness is presented. The method comprises: patterning a surface of a substrate to create an array of spaced-apart regions of a light sensitive material; applying a controllable etching to the patterned surface, said controllable etching being of a predetermined duration selected so as to form a pattern with nano-scale features; and removing the light sensitive material, thereby creating a structure with the nano-scale surface roughness. Silanizing such nano-scale roughness surface with hydrophobic molecules results in the creation of super-hydrophobic properties characterized by both a large contact angle and a large tilting angle. Also, deposition of a photo-active material on the nano-scale roughness surface results in a photocathode with enhanced photoemission yield. This method also provides for fabrication of a photocathode insensitive to polarization of incident light.Type: ApplicationFiled: September 12, 2010Publication date: January 13, 2011Applicant: Yeda Research and Development Company Ltd. Israeli Company, At The Weizmann Institute of ScienceInventors: Ron NAAMAN, Ben GOLAN, Zeev FRADKIN, Adam WINKLEMAN, Dan ORON
-
Publication number: 20100291036Abstract: The present invention relates to compounds and methods for inhibiting the expression of vascular endothelial growth factor-C (VEGF-C) in a target cell. Particularly, the present invention relates to antisense polynucleotides complementary to a lens epithelium-derived growth factor (LEDGF/p75) mRNA and uses thereof for inhibiting tumor progression and tumor metastasis. The present invention further relates to uses of LEDGF/p75 polypeptide or a nucleic acid encoding same for treating endothelial cell related conditions, particularly inflammation and edema.Type: ApplicationFiled: January 25, 2009Publication date: November 18, 2010Applicant: YEDA RESEARCH AND DEVELOPMENT CO.LTD, at The Weizmann Institute of ScienceInventors: Michal Neeman, Batya Cohen, Stav Sapoznik, Shifra Ben-Dor, Gila Meir
-
Publication number: 20100292604Abstract: A method of monitoring amount of milk consumed by an infant being breastfed by a breast is disclosed. The method comprises: determining variations in electric capacitance of the breast during breastfeeding, and correlating the electric capacitance variations to an amount of milk consumed by the infant.Type: ApplicationFiled: January 21, 2009Publication date: November 18, 2010Applicant: Yeda Research And Development Co., Ltd. at the Weizmann Institute of ScienceInventors: Ruti Kapon, Arik Peled, Shahar Seifer, Revital Schneider